Chengdu-headquartered biotech company HitGen Inc, which is backed by CDH Investments, is seeking to raise a total of 835 million yuan ($118 million) in its initial public offering (IPO) on China’s Nasdaq-like STAR Market.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
